Price
505.35
-0.17%52W Range
Market Cap
₹6,281.54 Cr
Traded: ₹15.55 Cr (0.25%) 0.0x
Free Float: ₹1,671.52 Cr (0.93% of FF traded)
Volume · 60D trend
3.06 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | -- | -- | -- | -- | -- | -- |
| Return | -- | -- | +82.0% | +9.0% | -- | Decelerating |
| Profit | -- | -- | +88.0% | -- | +103.0% | Accelerating |
| Sales | -- | -- | +58.0% | -- | +57.0% | Decelerating |
Quarterly Results
Dec 2024
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024 | Sep 2024PDF ↗ | |
|---|---|---|---|---|---|---|---|---|
| Sales | 224 | 216 | 222 | 190 | 174 | 139 | 116 | 114 |
| Expenses | 132 | 138 | 121 | 98 | 96 | 93 | 86 | 74 |
| Operating Profit | 92 | 78 | 101 | 92 | 79 | 46 | 30 | 40 |
| OPM % | 41.0% | 36.0% | 45.0% | 48.0% | 45.0% | 33.0% | 26.0% | 35.0% |
| Other Income | 14 | 3 | 3 | 1 | 1 | 0 | 0 | 3 |
| Interest | 3 | 4 | 3 | 4 | 2 | 3 | 4 | 2 |
| Depreciation | 15 | 16 | 11 | 10 | 10 | 9 | 8 | 6 |
| Profit Before Tax | 88 | 61 | 89 | 79 | 69 | 34 | 18 | 35 |
| Tax % | 25.0% | 26.0% | 25.0% | 25.0% | 25.0% | 25.0% | 26.0% | 25.0% |
| Net Profit | 66 | 45 | 67 | 59 | 51 | 25 | 13 | 27 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 5.3 | 3.6 | 5.4 | 4.7 | 4.1 | 2.0 | 1.1 | 2.1 |
| Sales Growth (YoY) | 28.7% | 55.4% | 91.4% | 66.7% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 3.7% | -2.7% | 16.8% | 9.2% | 25.2% | 19.8% | 1.8% | -- |
| OP Growth (YoY) | 16.5% | 69.6% | 236.7% | 130.0% | -- | -- | -- | -- |
| OP Growth (QoQ) | 17.9% | -22.8% | 9.8% | 16.5% | 71.7% | 53.3% | -25.0% | -- |
| Profit Growth (YoY) | -- | 78.0% | 405.0% | 121.0% | -- | -- | -- | -- |
| EPS Growth (YoY) | 28.6% | 77.9% | 405.7% | 121.0% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 46.3% | -32.3% | 13.3% | 14.5% | 102.5% | 92.5% | -50.5% | -- |
| OP Margin | 41.1% | 36.1% | 45.5% | 48.4% | 45.4% | 33.1% | 25.9% | 35.1% |
| Net Margin | 29.5% | 20.8% | 30.2% | 31.1% | 29.3% | 18.0% | 11.2% | 23.7% |
| Material Cost % | -- | 11.6% | 10.9% | 12.7% | 10.5% | 12.0% | 13.6% | 9.5% |
| Employee Cost % | -- | 21.3% | 17.7% | 17.5% | 17.2% | 20.6% | 23.1% | 20.9% |
| P/S | 7.37 | 9.27 | 10.89 | -- | -- | -- | -- | -- |
| P/E | 26.56 | 33.53 | 40.27 | -- | -- | -- | -- | -- |
| P/B | 13.45 | 15.92 | 21.59 | -- | -- | -- | -- | -- |
Exchange Filings
50Press Release titled JSLL Shares Update on IPD Growth and Business Mix
Publication of Case Studies
Publication of Case Studies
Submission of Transcript of Earnings Conference Call for the quarter ended 30 June, 2026.
Capacity Addition
Submission of audio recording of Earnings Conference Call - Q1 FY 2026-27
Jeena Sikho Lifecare Limited has informed the Exchange regarding the Investor Presentation.
Submission of Newspaper Advertisement Clipping of Extract of the Unaudited (Standalone and Consolidated) Financial Results for the Quarter ended June 30, 2026.
As per PDF of Outcome of Board Meeting attached.
Reappointment of Mr. Karan Vir Bindra as Independent Director, Mrs. Bhavna Grover as Whole time Director and Mr. Manish Grover as Managing Director, subject to approval of shareholders. ....
1. Approval of Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2026 along with Limited Review Report. 2. Re-appointment of Mr. Karan Vir Bindra (DIN: ....
Jeena Sikho Lifecare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 ,inter alia, to consider and approve 1. The Unaudited Financial ....
Launch of Four (4) new Products
Expansion of operational infrastructure through establishment of a New client Support Centre Facility at Noida, Uttar Pradesh
Proposal for Establishment of a New Hospital Facility at Kalyani, West Bengal
Outcome of Board Meeting held on 15th July, 2026: 1. Resignation of Mrs. Smita Chaturvedi as the Company Secretary and Compliance Officer as well as key Managerial Personnel of the Company 2. ....
Resignation of Mrs. Smita Chaturvedi as the Company Secretary and Compliance Officer as well as Key Managerial Personnel of the Company
1. Appointment of Mr. Ajay Sharma as an Additional Director (Non-Executive Independent Director Category) wef 15th July, 2026 2. Appointment of Mrs. Sapna Singh as an Additional Director ....
Appointment of Ms. Priya Goyal as the Company Secretary and Compliance Officer as well as Key Managerial Personnel of the Company wef 15th July, 2026.
Receipt of GST Appreciation Certificates from the Central Board of Indirect Taxes and Customs (CBIC)
Certificate Under Reg 74 (5) of SEBI (DP) Regulation, 2018
Intimation of closure of trading window pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 for the quarter ending 30th June, 2026.
Sale of land and building
Intimation of Analyst / Investor meet under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 scheduled to be held on 23rd June, 2026.
Execution of Memorandum of Understanding Cum Research Facility Usage Agreement.
Proposal for Establishment of a New Hospital Facility in Lucknow, Uttar Pradesh
Update about Establishment of a new day care Clinic.
Commencement of Operations of New Hospital Facility at Mathura, Uttar Pradesh.
Intimation of Investor/Analysts Meet/Conference under Regulation 30 of SEBI LODR Regulations, 2015 scheduled to be held on Friday, 12th June, 2026.
Submission of Transcript of Earnings Conference Call for the quarter and financial year ended 31st March, 2026.
Submission of audio recording of Earning Conference Call.
This is in continuation of our earlier intimation dated 31st May, 2026-Submission of revised investor presentation
Submission of Advertisement Clipping of Extract of the Audited (Standalone and Consolidated) Financial Results for the Quarter and Financial Year ended 31st March 2026.
Investor Presentation under Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Re-Appointment of M/s Forviz Mazars LLP as the Internal Auditor of the Company for financial year 2026-27.
Recommendation of Final Dividend of Rs. 4.50/- per equity share.
1. Approval of Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended 31st March, 2026. 2. Recommendation of Final Dividend of Rs. 4.50/- per ....
1. Approval of Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended 31st March, 2026. 2. Recommendation of Final Dividend of Rs. 4.50/- per ....
Annual Secretarial Compliance Report for the financial year ended 31st March 2026
Intimation of Earnings Conference Call for Investors and Analysts for Q4 FY26
Publication of Case Studies and Case Reports.
Prior Intimation of Board Meeting scheduled to be held on Saturday, 30/05/2026
Jeena Sikho Lifecare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve Prior Intimation of Meeting ....
Revised Disclosure under Regulation 30 of SEBI (LODR) Regulation, 2015 - Sale of Land
Disclosure under Regulation 30 of SEBI (LODR) Regulation, 2015- Sale of Land.
Appointment of GoIndia Advisors LLP as the Investor Relations Management Agency of the Company.
Please Refer to the attached PDF
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Receipt of NABH Accreditation for Noida Hospital.
Execution of Strategic Memorandum of Understanding (MOU) with Sat Kartar Life Limited
Concalls
12Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025Aug 2025
31 Aug 2025Jul 2025
31 Jul 2025May 2025
31 May 2025Nov 2024
30 Nov 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Aug 2023
31 Aug 2023Aug 2023
31 Aug 2023Held by ETFs
1 ETFs hold jsll · sorted by weight
Held by Mutual Funds
3 schemes hold jsll · sorted by weight